Want to see CUE full AI Analyst Report?
Top Page
Cue Biopharma
(NASDAQ:CUE)
Select Model
Select Model
Rating:57Neutral
Price Target:
$28.00
▼(-12.83% Downside)
Action:Reiterated
Date:07/11/26
The score is held back primarily by weak financial performance (large losses and ongoing cash burn), partially offset by very strong technical momentum (price well above key moving averages with positive MACD). Corporate events provide additional support through new funding and pipeline expansion, while valuation remains constrained due to negative earnings and no dividend yield data.
Positive Factors
High gross margin & revenue growth
Sustained revenue improvement and a ~72.6% gross margin indicate the company’s core platform produces high-margin recorded revenue. Over months, strong unit economics can allow scalable R&D leverage and better operating leverage as clinical programs progress and recorded revenue sources expand.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow means the company depends on external capital to fund operations. Over the next several months that structural cash burn raises refinancing and dilution risk and constrains ability to scale programs without additional financings or partner funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin & revenue growth
Sustained revenue improvement and a ~72.6% gross margin indicate the company’s core platform produces high-margin recorded revenue. Over months, strong unit economics can allow scalable R&D leverage and better operating leverage as clinical programs progress and recorded revenue sources expand.
Read all positive factors
Cue Biopharma (CUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$112.74M
Dividend YieldN/A
Average Volume (3M)121.76K
Price to Earnings (P/E)―
Beta (1Y)2.86
Revenue Growth309.60%
EPS Growth72.33%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.52
Shares Outstanding4,200,343
10 Day Avg. Volume146,729
30 Day Avg. Volume121,763
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.09
Price to Sales (P/S)1.05
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.64
Revenue Forecast (FY)$12.80M
Cue Biopharma Business Overview & Revenue Model
Company Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various...
How the Company Makes Money
Cue Biopharma does not have publicly established, recurring product sales from approved therapies; its revenue has primarily been generated through collaboration-related arrangements and other sources typical of clinical-stage biotech companies. K...
Cue Biopharma Earnings Call Summary
Earnings Call Date:Aug 19, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.Positive Updates
CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Negative Updates
Delays in Capital-Intensive Trials
Measures to delay the launch of capital-intensive trials were implemented, affecting the pace of certain developments.
Read all updates
Q2-2024 Updates
Positive
Negative
CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Read all positive updates
Company Guidance
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.Cue Biopharma Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.73M | 27.47M | 9.29M | 5.49M | 1.25M | 14.94M |
| Gross Profit | 32.65M | 27.47M | 9.29M | -32.61M | 1.25M | 16.72M |
| EBITDA | -15.84M | -22.27M | -37.53M | -46.05M | -50.49M | -45.44M |
| Net Income | -19.52M | -26.60M | -40.67M | -50.73M | -53.01M | -44.16M |
Balance Sheet | ||||||
| Total Assets | 30.88M | 42.21M | 32.19M | 61.53M | 91.28M | 83.40M |
| Cash, Cash Equivalents and Short-Term Investments | 16.38M | 27.14M | 23.39M | 48.51M | 76.29M | 64.37M |
| Total Debt | 3.44M | 4.20M | 8.88M | 14.70M | 19.32M | 12.02M |
| Total Liabilities | 9.27M | 15.78M | 14.69M | 24.45M | 25.60M | 17.91M |
| Stockholders Equity | 21.61M | 26.43M | 17.50M | 37.09M | 65.68M | 65.49M |
Cash Flow | ||||||
| Free Cash Flow | -24.61M | -21.86M | -36.40M | -39.96M | -41.98M | -39.75M |
| Operating Cash Flow | -24.46M | -21.69M | -36.33M | -39.96M | -41.81M | -38.84M |
| Investing Cash Flow | 104.00K | 75.00K | 32.00K | 25.00M | -24.61M | 9.11M |
| Financing Cash Flow | 27.60M | 26.29M | 10.24M | 11.86M | 53.66M | 19.23M |
Cue Biopharma Technical Analysis
Negative
32.12
Price Trends
28.38
Negative
22.24
Positive
18.14
Positive
Market Momentum
1.33
Positive
53.55
Neutral
58.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 32.12 is above the 20-day moving average (MA) of 31.80, above the 50-day MA of 28.38, and above the 200-day MA of 18.14, indicating a neutral trend. The MACD of 1.33 indicates Positive momentum. The RSI at 53.55 is Neutral, neither overbought nor oversold. The STOCH value of 58.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.
Cue Biopharma Risk Analysis
Cue Biopharma disclosed 66 risk factors in its most recent earnings report. Cue Biopharma reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cue Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $112.74M | -4.86 | -98.30% | ― | 309.60% | 72.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $26.18M | -0.49 | -139.47% | ― | 43.88% | 14.79% | |
44 Neutral | $76.00M | -1.83 | -284.80% | ― | ― | 16.55% | |
42 Neutral | $18.39M | -0.17 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $64.20M | -0.75 | -64.43% | ― | ― | 9.80% |
* Healthcare Sector Average
CUE
Cue Biopharma
26.84
3.98
17.41%
CELU
Celularity
0.64
-2.53
-79.91%
ALGS
Aligos Therapeutics
4.23
-3.77
-47.12%
GNTA
Genenta Science SpA Sponsored ADR
1.49
-2.21
-59.73%
MAIA
MAIA Biotechnology, Inc.
1.25
-0.33
-20.89%
ACRV
Acrivon Therapeutics, Inc.
1.50
0.17
12.78%
Cue Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Cue Biopharma Announces $50 Million Private Placement
Positive
Jul 10, 2026
On July 9, 2026, Cue Biopharma entered into a securities purchase agreement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to raise approximately $50 million through a private placement of co...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Cue Biopharma Shareholders Approve 2026 Stock Incentive Plan
Positive
Jun 3, 2026
At a special meeting of stockholders held on June 1, 2026, Cue Biopharma shareholders approved the company’s 2026 Stock Incentive Plan, formalizing a new equity-based compensation framework previously adopted by the board. The plan’s a...
Business Operations and StrategyExecutive/Board Changes
Cue Biopharma Streamlines Governance and Strengthens Leadership Team
Positive
Jun 2, 2026
On May 29, 2026, Cue Biopharma announced that directors Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen resigned from its board and board committees by mutual agreement, with the company emphasizing there were no disagreements rela...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.